Vyome Holdings, Inc. (HIND) 10-Year Financial Performance & Capital Metrics

HIND • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutVyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.Show more

Revenue $8M -7.7%
EBITDA -$8M +46.8%
Net Income -$7M +37.4%
EPS (Diluted) -345.74 +87.5%
Gross Margin 63.17% -1.2%
EBITDA Margin -96.25% +42.3%
Operating Margin -96.53% +42.8%
Net Margin -89.06% +32.1%
ROE -222.46% -0.8%
ROIC -485.63% +50.4%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Efficient asset utilization: 1.7x turnover

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Sales declining 11.9% over 5 years
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-11.91%

3Y-16.19%

TTM-48.74%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-62.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM78.21%

ROCE

10Y Avg-167.88%

5Y Avg-162.85%

3Y Avg-204.16%

Latest-228.71%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	292K	786.66K	1.29M	606.71K	15.09M	11.3M	13.6M	11.24M	8.68M	8.01M
Revenue Growth %	-	1.69%	0.64%	-0.53%	23.87%	-0.25%	0.2%	-0.17%	-0.23%	-0.08%
Cost of Goods Sold+	125K	431.48K	936.39K	164.3K	5.78M	5.04M	5.25M	4.44M	3.13M	2.95M
COGS % of Revenue	0.43%	0.55%	0.73%	0.27%	0.38%	0.45%	0.39%	0.39%	0.36%	0.37%
Gross Profit+	167K	355.18K	350.77K	442.41K	9.3M	6.26M	8.35M	6.8M	5.55M	5.06M
Gross Margin %	0.57%	0.45%	0.27%	0.73%	0.62%	0.55%	0.61%	0.61%	0.64%	0.63%
Gross Profit Growth %	-	1.13%	-0.01%	0.26%	20.03%	-0.33%	0.33%	-0.19%	-0.18%	-0.09%
Operating Expenses+	28.03M	23.15M	31.76M	24.98M	33.77M	18.72M	66.23M	33.88M	20.19M	12.79M
OpEx % of Revenue	96.01%	29.43%	24.67%	41.18%	2.24%	1.66%	4.87%	3.01%	2.33%	1.6%
Selling, General & Admin	19.89M	17.98M	25.98M	19.26M	22.07M	15.22M	33.21M	31.34M	17.87M	9.92M
SG&A % of Revenue	68.12%	22.86%	20.19%	31.75%	1.46%	1.35%	2.44%	2.79%	2.06%	1.24%
Research & Development	8.14M	5.17M	5.78M	5.72M	3.12M	3.5M	2.37M	2.54M	2.31M	1.8M
R&D % of Revenue	27.88%	6.57%	4.49%	9.43%	0.21%	0.31%	0.17%	0.23%	0.27%	0.23%
Other Operating Expenses	0	0	-652	-10.64K	8.57M	0	30.65M	0	0	1.06M
Operating Income+	-27.87M	-22.8M	-31.41M	-38.55M	-24.46M	-12.46M	-57.88M	-27.08M	-14.64M	-7.73M
Operating Margin %	-95.43%	-28.98%	-24.4%	-63.53%	-1.62%	-1.1%	-4.26%	-2.41%	-1.69%	-0.97%
Operating Income Growth %	-0.09%	0.18%	-0.38%	-0.23%	0.37%	0.49%	-3.65%	0.53%	0.46%	0.47%
EBITDA+	-27.68M	-22.6M	-31.08M	-37.96M	-22.75M	-10.79M	-55.91M	-24.93M	-14.48M	-7.71M
EBITDA Margin %	-94.79%	-28.73%	-24.14%	-62.58%	-1.51%	-0.95%	-4.11%	-2.22%	-1.67%	-0.96%
EBITDA Growth %	-0.09%	0.18%	-0.37%	-0.22%	0.4%	0.53%	-4.18%	0.55%	0.42%	0.47%
D&A (Non-Cash Add-back)	188.61K	192K	330K	581K	1.71M	1.67M	1.97M	2.15M	154K	22K
EBIT	-27.87M	-19.99M	-32.78M	-37.15M	-74.65M	-19.76M	-62.59M	-46.48M	-11.34M	-6.67M
Net Interest Income+	-937.36K	-4.1M	-2.81K	-12K	-451K	-2.05M	-832K	-113K	26K	14K
Interest Income	1.82K	5.84K	1.07K	0	0	0	0	0	26K	14K
Interest Expense	939.18K	4.1M	3.87K	12K	451K	2.05M	832K	113K	0	0
Other Income/Expense	2.37M	-565.22K	-1.37M	-167.73K	-50.64M	-9.35M	-5.54M	-19.52M	3.3M	637K
Pretax Income+	-25.5M	-23.36M	-36.13M	-38.71M	-75.1M	-21.81M	-63.42M	-46.59M	-11.34M	-7.09M
Pretax Margin %	-87.33%	-29.7%	-28.07%	-63.81%	-4.98%	-1.93%	-4.66%	-4.15%	-1.31%	-0.89%
Income Tax+	-2.56M	0	-2.31M	-3.45M	-893K	-181K	-274K	-380K	52K	39K
Effective Tax Rate %	1%	1%	0.94%	2.1%	0.99%	0.99%	1%	0.99%	1%	1.01%
Net Income+	-25.5M	-23.36M	-33.82M	-81.15M	-74.21M	-21.63M	-63.15M	-46.21M	-11.39M	-7.13M
Net Margin %	-87.33%	-29.7%	-26.27%	-133.76%	-4.92%	-1.91%	-4.64%	-4.11%	-1.31%	-0.89%
Net Income Growth %	0.02%	0.08%	-0.45%	-1.4%	0.09%	0.71%	-1.92%	0.27%	0.75%	0.37%
Net Income (Continuing)	-25.5M	-23.36M	-30.46M	-35.27M	-74.21M	-21.63M	-63.15M	-46.21M	-11.39M	-7.13M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-503023.26	-419004.00	-157897.00	-2771.94	-345.74
EPS Growth %	-0.57%	-4.21%	0.57%	0.06%	0.74%	0.54%	0.17%	0.62%	0.98%	0.88%
EPS (Basic)	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-503023.26	-419004.00	-157897.00	-2771.94	-345.74
Diluted Shares Outstanding	8	0	8	9	22	43	151	293	4.11K	20.62K
Basic Shares Outstanding	8	0	8	9	22	43	151	293	4.11K	20.62K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.5M	5.72M	13.94M	8.72M	10.11M	8.94M	29.94M	9.91M	10.3M	4.59M
Cash & Short-Term Investments	7.93M	3.31M	10.16M	5.55M	2.94M	3.01M	22.77M	3.96M	4.56M	693K
Cash Only	7.93M	3.31M	10.16M	5.55M	2.94M	3.01M	22.77M	3.96M	4.56M	693K
Short-Term Investments	0	2.5M	23.29M	0	0	0	0	0	0	0
Accounts Receivable	57.93K	143.69K	488.61K	917K	4.1M	2.62M	2.81M	2.18M	1.66M	1.03M
Days Sales Outstanding	72.41	66.67	138.56	551.67	99.08	84.64	75.55	70.79	69.78	46.87
Inventory	1.69M	1.79M	2.82M	984.74K	1.32M	2.24M	3M	3.61M	3.74M	2.46M
Days Inventory Outstanding	4.92K	1.51K	1.1K	2.19K	83.11	162.61	208.7	296.98	436.25	304.48
Other Current Assets	-987	319	848.57K	147K	215K	159K	238K	84K	126K	114K
Total Non-Current Assets+	1.08M	1.32M	74.77M	37.55M	29.55M	30.77M	22.59M	1.35M	431K	205K
Property, Plant & Equipment	326K	201K	439K	63.55K	774K	1.05M	1.72M	869K	310K	154K
Fixed Asset Turnover	0.90x	3.91x	2.93x	9.55x	19.49x	10.77x	7.91x	12.93x	27.99x	51.99x
Goodwill	0	0	27.19M	0	0	0	0	0	0	0
Intangible Assets	0	0	46.15M	36.93M	28.67M	27.02M	20.83M	260K	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	759K	1.12M	989K	562.86K	99K	46K	46K	46K	29K	29K
Total Assets+	11.59M	7.04M	88.7M	46.27M	39.66M	39.71M	52.53M	11.27M	10.73M	4.79M
Asset Turnover	0.03x	0.11x	0.01x	0.01x	0.38x	0.28x	0.26x	1.00x	0.81x	1.67x
Asset Growth %	-0.19%	-0.39%	11.6%	-0.48%	-0.14%	0%	0.32%	-0.79%	-0.05%	-0.55%
Total Current Liabilities+	4.49M	1.31M	1.09M	8.36M	10.39M	11.61M	7.53M	7.48M	3.78M	4.99M
Accounts Payable	172.05K	1.31M	1.09M	1.63M	4.26M	3.65M	3.47M	1.93M	1.69M	2.21M
Days Payables Outstanding	502.39	1.11K	424.2	3.61K	269.02	264.86	241.02	158.4	196.96	273.29
Short-Term Debt	717.39K	0	1.96M	9.93M	1.91M	3.92M	0	171K	111K	811K
Deferred Revenue (Current)	-549.56K	0	510K	352K	0	0	549K	0	0	720K
Other Current Liabilities	0	-2.24M	-1.01M	-6.88M	1.39M	2.03M	600K	3.44M	1.22M	207K
Current Ratio	2.34x	4.36x	12.81x	1.04x	0.97x	0.77x	3.98x	1.32x	2.73x	0.92x
Quick Ratio	1.97x	3.00x	10.22x	0.92x	0.85x	0.58x	3.58x	0.84x	1.74x	0.43x
Cash Conversion Cycle	4.49K	471.28	812.41	-875.16	-86.83	-17.61	43.23	209.37	309.07	78.06
Total Non-Current Liabilities+	3.43M	2.79M	11.25M	6.25M	5.16M	13.62M	667K	123K	287K	61K
Long-Term Debt	549.79K	9.88M	7.96M	0	2.73M	9.17M	0	0	0	0
Capital Lease Obligations	0	0	0	0	477K	163K	0	0	151K	41K
Deferred Tax Liabilities	0	0	5.29M	1.84M	0	3.27M	367K	123K	64K	0
Other Non-Current Liabilities	2.88M	-9.84M	-2.67M	6.25M	1.96M	1.02M	300K	0	72K	20K
Total Liabilities	7.91M	4.1M	12.34M	14.61M	15.55M	25.23M	8.2M	7.6M	4.06M	5.05M
Total Debt+	1.27M	143.69K	488.61K	6.31M	5.41M	13.25M	279K	171K	262K	967K
Net Debt	-6.66M	-3.17M	-9.67M	762.47K	2.47M	10.25M	-22.49M	-3.78M	-4.3M	274K
Debt / Equity	0.34x	0.05x	0.01x	0.20x	0.22x	0.91x	0.01x	0.05x	0.04x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-29.67x	-5.55x	-8107.35x	-3212.16x	-54.24x	-6.08x	-69.57x	-239.63x	-	-
Total Equity+	3.67M	2.94M	76.37M	31.66M	24.11M	14.49M	44.33M	3.66M	6.66M	-253K
Equity Growth %	-0.45%	-0.2%	24.98%	-0.59%	-0.24%	-0.4%	2.06%	-0.92%	0.82%	-1.04%
Book Value per Share	478270.15	0.18	999999.00	999999.00	999999.00	336930.23	294177.70	12508.42	1622.35	-12.27
Total Shareholders' Equity	3.67M	2.94M	76.37M	31.66M	24.11M	14.49M	44.33M	3.66M	6.66M	-253K
Common Stock	71.64K	27.37K	309.57K	87.7K	0	4K	0	1K	23K	0
Retained Earnings	-277.58M	-300.94M	-334.76M	-418.99M	-493.2M	-514.83M	-577.97M	-624.19M	-635.57M	-642.7M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-2.62M	-2.76M	-2.97M	-3.14M	-8K	-121K	-92K	-88K	-88K	-104K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-22.61M	-20.66M	-24.59M	-27.49M	-14.2M	-8.55M	-15.38M	-21.9M	-16.96M	-4.43M
Operating CF Margin %	-77.42%	-26.26%	-19.1%	-45.31%	-0.94%	-0.76%	-1.13%	-1.95%	-1.95%	-0.55%
Operating CF Growth %	-0.17%	0.09%	-0.19%	-0.12%	0.48%	0.4%	-0.8%	-0.42%	0.23%	0.74%
Net Income	-25.5M	-23.36M	-33.82M	-35.27M	-74.21M	-21.63M	-35.46M	-46.21M	-11.39M	-7.13M
Depreciation & Amortization	188.61K	139.58K	925.46K	440.56K	1.71M	1.67M	1.97M	2.15M	154K	22K
Stock-Based Compensation	6.94M	2.33M	4.44M	3.1M	2.31M	0	12.23M	2.09M	766K	184K
Deferred Taxes	826.62K	1.86M	-2.31M	-3.45M	-1.14M	-86K	-60K	-423K	28K	6K
Other Non-Cash Items	-3.3M	-3.51M	4.73M	6.83M	58.56M	11.49M	8.69M	19.79M	-2.39M	200K
Working Capital Changes	-1.77M	1.89M	1.45M	857.22K	-1.43M	6K	-2.74M	709K	-4.13M	2.29M
Change in Receivables	-55.12K	-105.63K	28.1K	-507.89K	-3.62M	1.22M	-284K	678K	125K	560K
Change in Inventory	-705.8K	-103.25K	68.44K	1.98M	-332K	-1.18M	-369K	-1.19M	-465K	922K
Change in Payables	-222.64K	1.14M	-223.44K	317.08K	0	-992K	-1.48M	448K	-3.46M	820K
Cash from Investing+	-38.91K	-14K	-6.37M	-10.33M	-2.01M	-2.39M	1.85M	-92K	-10K	0
Capital Expenditures	-38.91K	-14K	-137.12K	-49.58K	-14K	-390K	-352K	-131K	-43K	0
CapEx % of Revenue	0.13%	0.02%	0.11%	0.08%	0%	0.03%	0.03%	0.01%	0%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-6.55M	20.81M	-20.8M	0	0	0	-600K	33K	0
Cash from Financing+	18.95M	16.05M	37.81M	33.2M	13.66M	11.07M	33.3M	3.13M	17.57M	677K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-8.7M	-749.79K	31.34M	-4.04M	13.38M	0	0	2.49M	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-22.64M	-20.67M	-24.73M	-27.54M	-14.21M	-8.94M	-15.73M	-22.03M	-17M	-4.43M
FCF Margin %	-77.55%	-26.28%	-19.21%	-45.39%	-0.94%	-0.79%	-1.16%	-1.96%	-1.96%	-0.55%
FCF Growth %	-0.16%	0.09%	-0.2%	-0.11%	0.48%	0.37%	-0.76%	-0.4%	0.23%	0.74%
FCF per Share	-999999.00	-1.23	-999999.00	-999999.00	-656828.87	-207906.98	-104356.31	-75279.46	-4140.00	-214.67
FCF Conversion (FCF/Net Income)	0.89x	0.88x	0.73x	0.34x	0.19x	0.40x	0.24x	0.47x	1.49x	0.62x
Interest Paid	0	0	0	0	0	0	296K	0	0	0
Taxes Paid	0	0	0	0	0	0	102K	5K	10K	12K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-493.35%	-706.62%	-85.28%	-150.24%	-266.12%	-112.09%	-214.7%	-192.58%	-220.59%	-222.46%
Return on Invested Capital (ROIC)	-	-	-70.88%	-58.33%	-62.19%	-36.42%	-186.38%	-186.96%	-978.98%	-485.63%
Gross Margin	57.19%	45.15%	27.25%	72.92%	61.67%	55.42%	61.38%	60.52%	63.93%	63.17%
Net Margin	-8732.53%	-2969.62%	-2627.34%	-13375.68%	-491.8%	-191.43%	-464.31%	-411.16%	-131.22%	-89.06%
Debt / Equity	0.34x	0.05x	0.01x	0.20x	0.22x	0.91x	0.01x	0.05x	0.04x	-
Interest Coverage	-29.67x	-5.55x	-8107.35x	-3212.16x	-54.24x	-6.08x	-69.57x	-239.63x	-	-
FCF Conversion	0.89x	0.88x	0.73x	0.34x	0.19x	0.40x	0.24x	0.47x	1.49x	0.62x
Revenue Growth	-	169.4%	63.62%	-52.86%	2387.02%	-25.12%	20.36%	-17.35%	-22.79%	-7.74%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Product	606.71K	-	-	-	-	-	-
Product Growth	-	-	-	-	-	-	-

Revenue by Geography

	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	6.89M
UNITED STATES Growth	-	-	-	-	-	-	-
Europe	-	-	1.82M	2.13M	1.25M	956K	687K
Europe Growth	-	-	-	16.61%	-41.14%	-23.64%	-28.14%
AUSTRALIA	-	-	-	-	-	-	392K
AUSTRALIA Growth	-	-	-	-	-	-	-
Non-US	-	-	-	-	-	-	40K
Non-US Growth	-	-	-	-	-	-	-
United States	-	-	-	10.3M	9.23M	7.13M	-
United States Growth	-	-	-	-	-10.36%	-22.71%	-
Australia	-	-	-	1.04M	688K	526K	-
Australia Growth	-	-	-	-	-33.78%	-23.55%	-
world	-	-	-	137K	70K	62K	-
world Growth	-	-	-	-	-48.91%	-11.43%	-
U	156.34K	13.31M	8.28M	-	-	-	-
U Growth	-	8412.58%	-37.82%	-	-	-	-
Non Us	3.47K	1.78M	114K	-	-	-	-
Non Us Growth	-	51196.83%	-93.60%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Vyome Holdings, Inc. (HIND) reported $4.2M in revenue for fiscal year 2024.

Vyome Holdings, Inc. (HIND) saw revenue decline by 7.7% over the past year.

Vyome Holdings, Inc. (HIND) reported a net loss of $11.5M for fiscal year 2024.

Dividend & Returns

Vyome Holdings, Inc. (HIND) has a return on equity (ROE) of -222.5%. Negative ROE indicates the company is unprofitable.

Vyome Holdings, Inc. (HIND) had negative free cash flow of $3.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Vyome Holdings, Inc. (HIND) 10-Year Financial Performance & Capital Metrics

HIND • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $8M -7.7%
EBITDA -$8M +46.8%
Net Income -$7M +37.4%
EPS (Diluted) -345.74 +87.5%
Gross Margin 63.17% -1.2%
EBITDA Margin -96.25% +42.3%
Operating Margin -96.53% +42.8%
Net Margin -89.06% +32.1%
ROE -222.46% -0.8%
ROIC -485.63% +50.4%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Efficient asset utilization: 1.7x turnover

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Sales declining 11.9% over 5 years
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-11.91%

3Y-16.19%

TTM-48.74%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-62.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM78.21%

ROCE

10Y Avg-167.88%

5Y Avg-162.85%

3Y Avg-204.16%

Latest-228.71%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	292K	786.66K	1.29M	606.71K	15.09M	11.3M	13.6M	11.24M	8.68M	8.01M
Revenue Growth %	-	1.69%	0.64%	-0.53%	23.87%	-0.25%	0.2%	-0.17%	-0.23%	-0.08%
Cost of Goods Sold+	125K	431.48K	936.39K	164.3K	5.78M	5.04M	5.25M	4.44M	3.13M	2.95M
COGS % of Revenue	0.43%	0.55%	0.73%	0.27%	0.38%	0.45%	0.39%	0.39%	0.36%	0.37%
Gross Profit+	167K	355.18K	350.77K	442.41K	9.3M	6.26M	8.35M	6.8M	5.55M	5.06M
Gross Margin %	0.57%	0.45%	0.27%	0.73%	0.62%	0.55%	0.61%	0.61%	0.64%	0.63%
Gross Profit Growth %	-	1.13%	-0.01%	0.26%	20.03%	-0.33%	0.33%	-0.19%	-0.18%	-0.09%
Operating Expenses+	28.03M	23.15M	31.76M	24.98M	33.77M	18.72M	66.23M	33.88M	20.19M	12.79M
OpEx % of Revenue	96.01%	29.43%	24.67%	41.18%	2.24%	1.66%	4.87%	3.01%	2.33%	1.6%
Selling, General & Admin	19.89M	17.98M	25.98M	19.26M	22.07M	15.22M	33.21M	31.34M	17.87M	9.92M
SG&A % of Revenue	68.12%	22.86%	20.19%	31.75%	1.46%	1.35%	2.44%	2.79%	2.06%	1.24%
Research & Development	8.14M	5.17M	5.78M	5.72M	3.12M	3.5M	2.37M	2.54M	2.31M	1.8M
R&D % of Revenue	27.88%	6.57%	4.49%	9.43%	0.21%	0.31%	0.17%	0.23%	0.27%	0.23%
Other Operating Expenses	0	0	-652	-10.64K	8.57M	0	30.65M	0	0	1.06M
Operating Income+	-27.87M	-22.8M	-31.41M	-38.55M	-24.46M	-12.46M	-57.88M	-27.08M	-14.64M	-7.73M
Operating Margin %	-95.43%	-28.98%	-24.4%	-63.53%	-1.62%	-1.1%	-4.26%	-2.41%	-1.69%	-0.97%
Operating Income Growth %	-0.09%	0.18%	-0.38%	-0.23%	0.37%	0.49%	-3.65%	0.53%	0.46%	0.47%
EBITDA+	-27.68M	-22.6M	-31.08M	-37.96M	-22.75M	-10.79M	-55.91M	-24.93M	-14.48M	-7.71M
EBITDA Margin %	-94.79%	-28.73%	-24.14%	-62.58%	-1.51%	-0.95%	-4.11%	-2.22%	-1.67%	-0.96%
EBITDA Growth %	-0.09%	0.18%	-0.37%	-0.22%	0.4%	0.53%	-4.18%	0.55%	0.42%	0.47%
D&A (Non-Cash Add-back)	188.61K	192K	330K	581K	1.71M	1.67M	1.97M	2.15M	154K	22K
EBIT	-27.87M	-19.99M	-32.78M	-37.15M	-74.65M	-19.76M	-62.59M	-46.48M	-11.34M	-6.67M
Net Interest Income+	-937.36K	-4.1M	-2.81K	-12K	-451K	-2.05M	-832K	-113K	26K	14K
Interest Income	1.82K	5.84K	1.07K	0	0	0	0	0	26K	14K
Interest Expense	939.18K	4.1M	3.87K	12K	451K	2.05M	832K	113K	0	0
Other Income/Expense	2.37M	-565.22K	-1.37M	-167.73K	-50.64M	-9.35M	-5.54M	-19.52M	3.3M	637K
Pretax Income+	-25.5M	-23.36M	-36.13M	-38.71M	-75.1M	-21.81M	-63.42M	-46.59M	-11.34M	-7.09M
Pretax Margin %	-87.33%	-29.7%	-28.07%	-63.81%	-4.98%	-1.93%	-4.66%	-4.15%	-1.31%	-0.89%
Income Tax+	-2.56M	0	-2.31M	-3.45M	-893K	-181K	-274K	-380K	52K	39K
Effective Tax Rate %	1%	1%	0.94%	2.1%	0.99%	0.99%	1%	0.99%	1%	1.01%
Net Income+	-25.5M	-23.36M	-33.82M	-81.15M	-74.21M	-21.63M	-63.15M	-46.21M	-11.39M	-7.13M
Net Margin %	-87.33%	-29.7%	-26.27%	-133.76%	-4.92%	-1.91%	-4.64%	-4.11%	-1.31%	-0.89%
Net Income Growth %	0.02%	0.08%	-0.45%	-1.4%	0.09%	0.71%	-1.92%	0.27%	0.75%	0.37%
Net Income (Continuing)	-25.5M	-23.36M	-30.46M	-35.27M	-74.21M	-21.63M	-63.15M	-46.21M	-11.39M	-7.13M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-503023.26	-419004.00	-157897.00	-2771.94	-345.74
EPS Growth %	-0.57%	-4.21%	0.57%	0.06%	0.74%	0.54%	0.17%	0.62%	0.98%	0.88%
EPS (Basic)	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-503023.26	-419004.00	-157897.00	-2771.94	-345.74
Diluted Shares Outstanding	8	0	8	9	22	43	151	293	4.11K	20.62K
Basic Shares Outstanding	8	0	8	9	22	43	151	293	4.11K	20.62K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.5M	5.72M	13.94M	8.72M	10.11M	8.94M	29.94M	9.91M	10.3M	4.59M
Cash & Short-Term Investments	7.93M	3.31M	10.16M	5.55M	2.94M	3.01M	22.77M	3.96M	4.56M	693K
Cash Only	7.93M	3.31M	10.16M	5.55M	2.94M	3.01M	22.77M	3.96M	4.56M	693K
Short-Term Investments	0	2.5M	23.29M	0	0	0	0	0	0	0
Accounts Receivable	57.93K	143.69K	488.61K	917K	4.1M	2.62M	2.81M	2.18M	1.66M	1.03M
Days Sales Outstanding	72.41	66.67	138.56	551.67	99.08	84.64	75.55	70.79	69.78	46.87
Inventory	1.69M	1.79M	2.82M	984.74K	1.32M	2.24M	3M	3.61M	3.74M	2.46M
Days Inventory Outstanding	4.92K	1.51K	1.1K	2.19K	83.11	162.61	208.7	296.98	436.25	304.48
Other Current Assets	-987	319	848.57K	147K	215K	159K	238K	84K	126K	114K
Total Non-Current Assets+	1.08M	1.32M	74.77M	37.55M	29.55M	30.77M	22.59M	1.35M	431K	205K
Property, Plant & Equipment	326K	201K	439K	63.55K	774K	1.05M	1.72M	869K	310K	154K
Fixed Asset Turnover	0.90x	3.91x	2.93x	9.55x	19.49x	10.77x	7.91x	12.93x	27.99x	51.99x
Goodwill	0	0	27.19M	0	0	0	0	0	0	0
Intangible Assets	0	0	46.15M	36.93M	28.67M	27.02M	20.83M	260K	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	759K	1.12M	989K	562.86K	99K	46K	46K	46K	29K	29K
Total Assets+	11.59M	7.04M	88.7M	46.27M	39.66M	39.71M	52.53M	11.27M	10.73M	4.79M
Asset Turnover	0.03x	0.11x	0.01x	0.01x	0.38x	0.28x	0.26x	1.00x	0.81x	1.67x
Asset Growth %	-0.19%	-0.39%	11.6%	-0.48%	-0.14%	0%	0.32%	-0.79%	-0.05%	-0.55%
Total Current Liabilities+	4.49M	1.31M	1.09M	8.36M	10.39M	11.61M	7.53M	7.48M	3.78M	4.99M
Accounts Payable	172.05K	1.31M	1.09M	1.63M	4.26M	3.65M	3.47M	1.93M	1.69M	2.21M
Days Payables Outstanding	502.39	1.11K	424.2	3.61K	269.02	264.86	241.02	158.4	196.96	273.29
Short-Term Debt	717.39K	0	1.96M	9.93M	1.91M	3.92M	0	171K	111K	811K
Deferred Revenue (Current)	-549.56K	0	510K	352K	0	0	549K	0	0	720K
Other Current Liabilities	0	-2.24M	-1.01M	-6.88M	1.39M	2.03M	600K	3.44M	1.22M	207K
Current Ratio	2.34x	4.36x	12.81x	1.04x	0.97x	0.77x	3.98x	1.32x	2.73x	0.92x
Quick Ratio	1.97x	3.00x	10.22x	0.92x	0.85x	0.58x	3.58x	0.84x	1.74x	0.43x
Cash Conversion Cycle	4.49K	471.28	812.41	-875.16	-86.83	-17.61	43.23	209.37	309.07	78.06
Total Non-Current Liabilities+	3.43M	2.79M	11.25M	6.25M	5.16M	13.62M	667K	123K	287K	61K
Long-Term Debt	549.79K	9.88M	7.96M	0	2.73M	9.17M	0	0	0	0
Capital Lease Obligations	0	0	0	0	477K	163K	0	0	151K	41K
Deferred Tax Liabilities	0	0	5.29M	1.84M	0	3.27M	367K	123K	64K	0
Other Non-Current Liabilities	2.88M	-9.84M	-2.67M	6.25M	1.96M	1.02M	300K	0	72K	20K
Total Liabilities	7.91M	4.1M	12.34M	14.61M	15.55M	25.23M	8.2M	7.6M	4.06M	5.05M
Total Debt+	1.27M	143.69K	488.61K	6.31M	5.41M	13.25M	279K	171K	262K	967K
Net Debt	-6.66M	-3.17M	-9.67M	762.47K	2.47M	10.25M	-22.49M	-3.78M	-4.3M	274K
Debt / Equity	0.34x	0.05x	0.01x	0.20x	0.22x	0.91x	0.01x	0.05x	0.04x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-29.67x	-5.55x	-8107.35x	-3212.16x	-54.24x	-6.08x	-69.57x	-239.63x	-	-
Total Equity+	3.67M	2.94M	76.37M	31.66M	24.11M	14.49M	44.33M	3.66M	6.66M	-253K
Equity Growth %	-0.45%	-0.2%	24.98%	-0.59%	-0.24%	-0.4%	2.06%	-0.92%	0.82%	-1.04%
Book Value per Share	478270.15	0.18	999999.00	999999.00	999999.00	336930.23	294177.70	12508.42	1622.35	-12.27
Total Shareholders' Equity	3.67M	2.94M	76.37M	31.66M	24.11M	14.49M	44.33M	3.66M	6.66M	-253K
Common Stock	71.64K	27.37K	309.57K	87.7K	0	4K	0	1K	23K	0
Retained Earnings	-277.58M	-300.94M	-334.76M	-418.99M	-493.2M	-514.83M	-577.97M	-624.19M	-635.57M	-642.7M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-2.62M	-2.76M	-2.97M	-3.14M	-8K	-121K	-92K	-88K	-88K	-104K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-22.61M	-20.66M	-24.59M	-27.49M	-14.2M	-8.55M	-15.38M	-21.9M	-16.96M	-4.43M
Operating CF Margin %	-77.42%	-26.26%	-19.1%	-45.31%	-0.94%	-0.76%	-1.13%	-1.95%	-1.95%	-0.55%
Operating CF Growth %	-0.17%	0.09%	-0.19%	-0.12%	0.48%	0.4%	-0.8%	-0.42%	0.23%	0.74%
Net Income	-25.5M	-23.36M	-33.82M	-35.27M	-74.21M	-21.63M	-35.46M	-46.21M	-11.39M	-7.13M
Depreciation & Amortization	188.61K	139.58K	925.46K	440.56K	1.71M	1.67M	1.97M	2.15M	154K	22K
Stock-Based Compensation	6.94M	2.33M	4.44M	3.1M	2.31M	0	12.23M	2.09M	766K	184K
Deferred Taxes	826.62K	1.86M	-2.31M	-3.45M	-1.14M	-86K	-60K	-423K	28K	6K
Other Non-Cash Items	-3.3M	-3.51M	4.73M	6.83M	58.56M	11.49M	8.69M	19.79M	-2.39M	200K
Working Capital Changes	-1.77M	1.89M	1.45M	857.22K	-1.43M	6K	-2.74M	709K	-4.13M	2.29M
Change in Receivables	-55.12K	-105.63K	28.1K	-507.89K	-3.62M	1.22M	-284K	678K	125K	560K
Change in Inventory	-705.8K	-103.25K	68.44K	1.98M	-332K	-1.18M	-369K	-1.19M	-465K	922K
Change in Payables	-222.64K	1.14M	-223.44K	317.08K	0	-992K	-1.48M	448K	-3.46M	820K
Cash from Investing+	-38.91K	-14K	-6.37M	-10.33M	-2.01M	-2.39M	1.85M	-92K	-10K	0
Capital Expenditures	-38.91K	-14K	-137.12K	-49.58K	-14K	-390K	-352K	-131K	-43K	0
CapEx % of Revenue	0.13%	0.02%	0.11%	0.08%	0%	0.03%	0.03%	0.01%	0%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-6.55M	20.81M	-20.8M	0	0	0	-600K	33K	0
Cash from Financing+	18.95M	16.05M	37.81M	33.2M	13.66M	11.07M	33.3M	3.13M	17.57M	677K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-8.7M	-749.79K	31.34M	-4.04M	13.38M	0	0	2.49M	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-22.64M	-20.67M	-24.73M	-27.54M	-14.21M	-8.94M	-15.73M	-22.03M	-17M	-4.43M
FCF Margin %	-77.55%	-26.28%	-19.21%	-45.39%	-0.94%	-0.79%	-1.16%	-1.96%	-1.96%	-0.55%
FCF Growth %	-0.16%	0.09%	-0.2%	-0.11%	0.48%	0.37%	-0.76%	-0.4%	0.23%	0.74%
FCF per Share	-999999.00	-1.23	-999999.00	-999999.00	-656828.87	-207906.98	-104356.31	-75279.46	-4140.00	-214.67
FCF Conversion (FCF/Net Income)	0.89x	0.88x	0.73x	0.34x	0.19x	0.40x	0.24x	0.47x	1.49x	0.62x
Interest Paid	0	0	0	0	0	0	296K	0	0	0
Taxes Paid	0	0	0	0	0	0	102K	5K	10K	12K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-493.35%	-706.62%	-85.28%	-150.24%	-266.12%	-112.09%	-214.7%	-192.58%	-220.59%	-222.46%
Return on Invested Capital (ROIC)	-	-	-70.88%	-58.33%	-62.19%	-36.42%	-186.38%	-186.96%	-978.98%	-485.63%
Gross Margin	57.19%	45.15%	27.25%	72.92%	61.67%	55.42%	61.38%	60.52%	63.93%	63.17%
Net Margin	-8732.53%	-2969.62%	-2627.34%	-13375.68%	-491.8%	-191.43%	-464.31%	-411.16%	-131.22%	-89.06%
Debt / Equity	0.34x	0.05x	0.01x	0.20x	0.22x	0.91x	0.01x	0.05x	0.04x	-
Interest Coverage	-29.67x	-5.55x	-8107.35x	-3212.16x	-54.24x	-6.08x	-69.57x	-239.63x	-	-
FCF Conversion	0.89x	0.88x	0.73x	0.34x	0.19x	0.40x	0.24x	0.47x	1.49x	0.62x
Revenue Growth	-	169.4%	63.62%	-52.86%	2387.02%	-25.12%	20.36%	-17.35%	-22.79%	-7.74%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Product	606.71K	-	-	-	-	-	-
Product Growth	-	-	-	-	-	-	-

Revenue by Geography

	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	6.89M
UNITED STATES Growth	-	-	-	-	-	-	-
Europe	-	-	1.82M	2.13M	1.25M	956K	687K
Europe Growth	-	-	-	16.61%	-41.14%	-23.64%	-28.14%
AUSTRALIA	-	-	-	-	-	-	392K
AUSTRALIA Growth	-	-	-	-	-	-	-
Non-US	-	-	-	-	-	-	40K
Non-US Growth	-	-	-	-	-	-	-
United States	-	-	-	10.3M	9.23M	7.13M	-
United States Growth	-	-	-	-	-10.36%	-22.71%	-
Australia	-	-	-	1.04M	688K	526K	-
Australia Growth	-	-	-	-	-33.78%	-23.55%	-
world	-	-	-	137K	70K	62K	-
world Growth	-	-	-	-	-48.91%	-11.43%	-
U	156.34K	13.31M	8.28M	-	-	-	-
U Growth	-	8412.58%	-37.82%	-	-	-	-
Non Us	3.47K	1.78M	114K	-	-	-	-
Non Us Growth	-	51196.83%	-93.60%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Vyome Holdings, Inc. (HIND) reported $4.2M in revenue for fiscal year 2024.

Vyome Holdings, Inc. (HIND) saw revenue decline by 7.7% over the past year.

Vyome Holdings, Inc. (HIND) reported a net loss of $11.5M for fiscal year 2024.

Dividend & Returns

Vyome Holdings, Inc. (HIND) has a return on equity (ROE) of -222.5%. Negative ROE indicates the company is unprofitable.

Vyome Holdings, Inc. (HIND) had negative free cash flow of $3.0M in fiscal year 2024, likely due to heavy capital investments.